TG Therapeutics completes enrollment in Phase 3 ENHANCE trial

TG Therapeutics (TGTX) announced that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for IV BRIUMVI, the company’s novel, glycoengineered, anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis. The primary endpoint of this trial is non inferior exposure with respect to area under the curve, AUC, at week 16. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “We are excited to announce the completion of enrollment in the randomized cohort of the ENHANCE Phase 3 trial, which opened for enrollment last quarter. The study is designed to evaluate whether consolidating the BRIUMVI Day 1 and Day 15 infusions into a single Day 1 infusion maintains the exposure seen with our existing approved regimen… We remain deeply committed to continuing to enhance the overall patient experience with BRIUMVI, and if the data are positive, this new dosing regimen could be ready for launch in 2027.”